The activity of intact urokinase (UK) and urokinases modified by soluble macromolecules (dextran and dextran sulfate sodium) in a mouse body was traced after injection of the 1251 labelled enzymes. The residual fraction of the enzyme in blood can be correlated with the time (t) as follows;
Introduction
Urokinase (UK) is a proteinase that has been widely used for the treatment of thrombosis. The circulatory half-life of UK in blood, however, is too short (less than 20 min in human blood), which limits the usefulness of UK. To increase the stability of UK in the blood, it was chemically modified with soluble macromolecules such as dextran and dextran sulfate sodium. The modified UK was more resistant to other proteinases and inhibitors in blood, and could be used more effectively for the treatment of thrombosis1).
In this work, a kinetic model for UK and modified UK in animal bodies was investigated and the modification effect on the medical treatment of thrombosis was theoretically estimated.
Materials and Methods

Materials
Urokinase was obtained from Dandong Victory Chemical Plant of China: specific activity, 52 000 IU/mg. pr.; M.W., 54 700 daltons. The mice (weight, 18±1 g) were obtained from Bethune Medical University. The radioisotope, Na125I, was obtained from The Nuclear Institute 
Experiment in animal body
In order to reduce the amount of iodine adsorbed onto the thyroid gland, drinking water containing 0.05% of KI was given to the mice two days before the experiment. The mice were divided into three groups: the first was used in experiments of UK-125I, the second was used in experiments of D-UK-125I and the third group was used in experiments of S-UK-125I . Each group was also divided into subgroups depending on the duration time of experiment, and five mice were used in each subgroup.
The UK-1251 and modified UK-1261
were injected into mice through the tail vein in a dose of 1.2 x 108 cpm/0.2 ml (about 2000 units of urokinase). The mice were dissected at intervals of defined time and the blood (0.2 ml) and objective tissues were isolated. The objective tissues were liver, kidney, heart, lung and spleen. The radioactivity of each sample was assayed to determine the amount of enzyme contained in the tissues.
Theoretical Method
After the injection of intact or modified UK, the radioactivity in blood fell rapidly and 20-30% radioactivity of the initial dose was found in the livers and kidneys after 3 min. The distribution of radioactivity in the heart, lung and spleen was less than 1 % of the administered radioactivity in our experiment. Within 24 h, the 63% and 1.4% of the administered radioactivity were recovered in the urine and blood is given as follows:
•¬(4) •¬ (10)
When A, B and C are constant, these equations can predict the distribution of the UK concentration in blood, liver and kidney.
Results and Treatment of Data
It was experimentally found that most of the UK-1`51 and modified UK 125I were distributed in blood, liver and kidney after injection, while the distribution in heart, lung and spleen was less than 1 % of the injection dose. The changes in distribution of the urokinases in blood, liver and kidney are shown in Tables 2, 3 , and 4.
Urokinases in blood
Based on the experiment of Woodard2', the behaviour of UK-125I in the blood of rat are shown in Table 1 . Using the experimental data, Eq. (10) was solved by the method of regression and the constants were obtained as follows:
•¬(13)
The theoretical curve of Eq. (13) is shown in Fig. 1 together with points of experimental data. It is clear that the theoretical curve is in good accordance with the experimental data. The experimental data of 
Urokinases in liver
The experimental data in Table 3 •¬(20)
The theoretical data and curves are shown in Fig. 3 .
Urokinases in kidney
The experimental data shown in Table  4 
Discussion
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